CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is -$286.8M, lower than 95% of all stocks globally
- PositionOperating margin is 41.3%, higher than 95% of its Biotechnology peers (median -24.1%)
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.99BUSDvs all stocks (USD)
Revenue (TTM)
1.01BUSDvs all stocks (USD)
Profit Margin
-3.81%vs Biotechnology peers
Beta
0.5450xvs all stocks
52-Week Change
45.57%vs all stocks
Market Capitalization
5.99BUSDvs all stocks (USD)
Enterprise Value
6.86BUSDvs all stocks (USD)
Forward P/E
29.08xvs Biotechnology peers
Price to Sales (TTM)
6.01xvs Biotechnology peers
Enterprise to Revenue
6.80xvs Biotechnology peers
Enterprise to EBITDA
40.04xvs Biotechnology peers
Gross Margin
94.47%vs Biotechnology peers
Profit Margin
-3.81%vs Biotechnology peers
Operating Margin
41.32%vs Biotechnology peers
Return on Assets (TTM)
2.46%vs Biotechnology peers
Revenue (TTM)
1.01BUSDvs all stocks (USD)
Revenue per Share (TTM)
12.35USDUpdated Aug 28, 2026Quarterly Revenue Growth
101.50%vs Biotechnology peers
Gross Profit (TTM)
503.96MUSDvs all stocks (USD)
EBITDA (TTM)
877.24MUSDvs all stocks (USD)
Net Income (TTM)
-38.38MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
101.55%vs Biotechnology peers
Operating Cash Flow (TTM)
-30.50MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-286.80MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
1.73BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
47.01MUSDFY2025 · Dec 31, 2025Gross Profit
1.68BUSDFY2025 · Dec 31, 2025Operating Income
856.51MUSDvs all stocks (USD)
Pre-tax Income
696.62MUSDFY2025 · Dec 31, 2025Income Tax Expense
13.97MUSDFY2025 · Dec 31, 2025Net Income
682.64MUSDFY2025 · Dec 31, 2025EBIT
848.85MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
877.24MUSDFY2025 · Dec 31, 2025Research & Development
455.25MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
347.14MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
152.23MUSDFY2025 · Dec 31, 2025EPS (Basic)
8.58USDFY2025 · Dec 31, 2025EPS (Diluted)
8.58USDFY2025 · Dec 31, 2025Basic Shares Outstanding
79.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
79.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
682.64MUSDFY2025 · Dec 31, 2025Operating Cash Flow
689.58MUSDFY2025 · Dec 31, 2025Free Cash Flow
680.79MUSDDerived from operating cash flow minus capital expenditure. This filing charges 38.82M of depreciation against 8.79M of capital expenditure, and its own free-cash-flow line reads 411.18M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
998.33MUSDFY2025 · Dec 31, 2025Income Tax Paid
36.85MUSDFY2025 · Dec 31, 2025Interest Paid
5.70MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
682.64MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
38.81MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-3.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
74.55MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-20.98MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-10.15MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-75.29MUSDFY2025 · Dec 31, 2025Capital Expenditures
-8.79MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-291.15MUSDFY2025 · Dec 31, 2025Purchase of Investments
-1.42BUSDFY2025 · Dec 31, 2025Sale of Investments
855.12MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-570.83MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.61MUSDFY2025 · Dec 31, 2025Other Financing Charges
233.66MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
232.05MUSDFY2025 · Dec 31, 2025Shares Outstanding
83.33MSharesUpdated Aug 28, 2026Float Shares
73.62MSharesUpdated Aug 28, 2026Shares Short
10.22MSharesUpdated Aug 28, 2026Short Ratio
8.26daysvs all stocks
Short % of Shares Outstanding
16.60%vs all stocks
% Held by Insiders
7.31%vs all stocks
% Held by Institutions
122.91%vs all stocks
Total Cash (MRQ)
2.23BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
26.71USDUpdated Aug 28, 2026Total Debt (MRQ)
3.02BUSDvs all stocks (USD)
Current Ratio (MRQ)
3.39xvs Biotechnology peers
Book Value per Share (MRQ)
-1.99USDUpdated Aug 28, 2026Total Assets
2.90BUSDvs all stocks (USD)
Total Current Assets
2.27BUSDFY2025 · Dec 31, 2025Total Liabilities
3.10BUSDFY2025 · Dec 31, 2025Total Non-current Assets
624.82MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.14BUSDFY2025 · Dec 31, 2025Total Current Liabilities
968.43MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
984.65MUSDFY2025 · Dec 31, 2025Other Short-term Investments
960.72MUSDFY2025 · Dec 31, 2025Accounts Receivable
181.62MUSDFY2025 · Dec 31, 2025Inventory
79.65MUSDFY2025 · Dec 31, 2025Accounts Payable
45.49MUSDFY2025 · Dec 31, 2025Short-term Debt
585.12MUSDFY2025 · Dec 31, 2025Deferred Revenue
2.04MUSDFY2025 · Dec 31, 2025Long-term Debt
2.12BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
13.70MUSDFY2025 · Dec 31, 2025Common Stock (Book)
80.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-2.96BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-205.31MUSDvs all stocks (USD)
52-Week Low
48.95USDUpdated Aug 28, 202652-Week High
90.87USDUpdated Aug 28, 202652-Week Change
45.57%vs all stocks
Beta
0.5450xvs all stocks
50-Day MA
77.19USDUpdated Aug 28, 2026200-Day MA
73.47USDUpdated Aug 28, 2026Avg 10-Day Volume
802.66KSharesUpdated Aug 28, 2026Avg 30-Day Volume
1.12MSharesUpdated Aug 28, 2026Diluted EPS (TTM)
-0.6600USDUpdated Aug 28, 2026Other Income / Expense
-7.66MUSDFY2025 · Dec 31, 20255 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 41.3%, higher than 95% of its Biotechnology peers (median -24.1%)Significant
Operating margin: 0.41Industry median: -0.24Industry P95: 0.38Peers compared: 194
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.94Profit Margin: -0.04
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is -$286.8M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -286,804,256Global P5: -209,187,555.994
Market cap is $5.99B, above the global median of $1.18BNotable
Market cap (USD): 5,993,320,191Global Median: 1,179,398,897.704
Revenue is $1.01B, above the global median of $534.05MNotable
Revenue (USD): 1,008,753,984Global Median: 534,052,387.958
Companies that share the same coordination system — how they create, deliver, or capture value.
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Mirum Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Definium Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sectra AB
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Xenon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Dianthus Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kiniksa Pharmaceuticals International, plc
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Salubris Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Liquidia Corporation
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Allist Pharmaceuticals Co., Ltd.
5 interpretationsThree Asset-Base Ratios ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsOperating Income Growing With Multi-Year Revenue GrowthCash-Flow Ratios ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Keeper Technical Laboratory
5 interpretationsThree Asset-Base Ratios ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsOperating Income Growing With Multi-Year Revenue GrowthCash-Flow Ratios ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Sk Biopharmaceuticals Co., Ltd.
5 interpretationsThree Asset-Base Ratios ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsOperating Income Growing With Multi-Year Revenue GrowthCash-Flow Ratios ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels